Personalis, Inc. (NASDAQ:PSNL) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Personalis, Inc. (NASDAQ:PSNL) have been given a consensus recommendation of “Moderate Buy” by the seven ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $11.6667.

PSNL has been the subject of a number of recent analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st. BTIG Research decreased their price objective on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. Finally, Morgan Stanley raised their target price on Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th.

Personalis Stock Performance

Shares of NASDAQ PSNL opened at $15.04 on Tuesday. The stock has a market capitalization of $1.57 billion, a P/E ratio of -14.75 and a beta of 2.24. The stock’s fifty day moving average is $10.18 and its 200 day moving average is $8.70. Personalis has a 52 week low of $3.84 and a 52 week high of $16.15.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). The firm had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.48 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. Equities research analysts forecast that Personalis will post -1.07 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Aaron Tachibana sold 51,251 shares of the company’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $13.18, for a total transaction of $675,488.18. Following the completion of the sale, the chief financial officer directly owned 198,833 shares in the company, valued at $2,620,618.94. This represents a 20.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher M. Hall sold 100,000 shares of the firm’s stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.15, for a total value of $1,315,000.00. Following the completion of the sale, the chief executive officer directly owned 235,986 shares in the company, valued at $3,103,215.90. This trade represents a 29.76% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 435,032 shares of company stock valued at $5,599,929 in the last three months. 4.20% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Aberdeen Group plc increased its position in Personalis by 36.1% during the 4th quarter. Aberdeen Group plc now owns 3,249,895 shares of the company’s stock worth $25,869,000 after purchasing an additional 861,948 shares in the last quarter. Oracle Investment Management Inc. acquired a new stake in Personalis in the third quarter valued at approximately $1,496,000. Howland Capital Management LLC boosted its position in Personalis by 65.5% in the fourth quarter. Howland Capital Management LLC now owns 547,115 shares of the company’s stock valued at $4,355,000 after buying an additional 216,442 shares in the last quarter. Next Century Growth Investors LLC bought a new stake in shares of Personalis during the fourth quarter worth $4,970,000. Finally, D.A. Davidson & CO. bought a new stake in shares of Personalis during the fourth quarter worth $1,158,000. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.